1-(2-溴乙基)-1H-咪唑氢溴酸盐 | 94614-84-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(2-溴乙基)-1H-咪唑氢溴酸盐
• 英文名称: 1-(2-bromoethyl)imidazole hydrogen bromide
• 英文别名: 1-(2-bromoethyl)-1H-imidazol-1-ium;bromide
• CAS: 94614-84-3
• 化学式: BrH*C₅H₇BrN₂
• mdl: MFCD16039341
• 分子量: 255.94
• InChiKey: MZNYYFODRQQSJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.93
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  17.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-溴乙基)-1H-咪唑氢溴酸盐 在 sodium hydroxide 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 5-[3-(2-Imidazol-1-ylethyl)-4-oxophthalazin-1-yl]thiophene-2-carboxylic acid
  参考文献：
  名称：

  Novel antiasthmatic agents with dual activities of thromboxane A2 synthetase inhibition and bronchodilation. 1. 2-[2-(1-Imidazolyl)alkyl]-1(2H)-phthalazinones

  摘要：

  A number of 4-substituted 2-[omega-(1-imidazolyl)allryl]-1(2H)-phthalazinones were synthesized in order to develop agents possessing both thromboxane Az synthetase inhibitory and bronchodilatory activities. The pharmacological evaluation of these compounds disclosed that they have both activities to various extents. Both activities were slightly dependent on the length of the 2-substituents and largely affected by the nature of the 4-substituents. Compounds bearing phenyl and thienyl groups exhibited relatively high and well-rounded activities. Among these compounds, 12j and 15f were found to be the most effective agents having well-rounded activities in vitro and in vivo. Introduction of a carboxyl group reduced both activities contrary to our expectation. 4-(3-Pyridyl)phthalazinone 18b was of particular interest because of unexpectedly high in vivo activities in spite of an absence of significant in vitro activities.

  DOI：

  10.1021/jm00077a008
• 作为产物：
  描述：

  1-hydroxyethylimidazole 在 二溴亚砜 作用下， 以 二氯甲烷 为溶剂， 生成 1-(2-溴乙基)-1H-咪唑氢溴酸盐
  参考文献：
  名称：

  2-(heterocycloalkylthio)penems

  摘要：

  本发明涉及2-(杂环烷硫基)青霉烷，其中杂环环的氮原子连接到烷基上，以及它们作为抗菌剂的使用。

  公开号：

  US04690922A1

文献信息

• [EN] DIHYDROPYRIDO PYRIMIDINE COMPOUNDS AS AUTOTAXIN INHIBITORS<br/>[FR] COMPOSÉS DIHYDROPYRIDO-PYRIMIDINE SERVANT D'INHIBITEURS DE L'AUTOTAXINE
  申请人：LILLY CO ELI

  公开号：WO2014168824A1

  公开（公告）日：2014-10-16

  The present invention provides compounds of the formula (I) or a pharmaceutically acceptable salt thereof. Compounds of the invention are autotaxin inhibitors useful in the treatment of pain associated with osteoarthritis.

  本发明提供了式(I)的化合物或其药学上可接受的盐。本发明的化合物是自体脂肪酶抑制剂，可用于治疗与骨关节炎相关的疼痛。
• Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. IV. 2-(2-(1-Imidazolyl)ethyl)-4-(3-pyridyl)-1(2H)-phthalazinones.
  作者：Masahisa YAMAGUCHI、Takaki KOGA、Kenshi KAMEI、Michitaka AKIMA、Noriaki MARUYAMA、Toshio KUROKI、Masatomo HAMANA、Nobuhiro OHI

  DOI：10.1248/cpb.42.1850

  日期：——

  Synthesis and pharmacological evaluation of several compounds related to 2-[2-(1-imidazolyl)ethyl]-4-(3-pyridyl)-1(2H)-phthalazinones are described. The phenyl moiety of the phthalazinone skeleton was found to play an important role in both thromboxane A2 synthetase-inhibitory and bronchodilatory activities. Further, the 3-pyridyl group at the 4-position was shown to be necessary for in vivo thromboxane

  描述了几种与2- [2-（1-咪唑基）乙基] -4-（3-吡啶基）-1（2H）-酞嗪酮有关的化合物的合成和药理学评价。发现酞嗪酮骨架的苯基部分在血栓烷A2合成酶抑制和支气管扩张活性中均起重要作用。此外，显示了在4-位的3-吡啶基对于体内血栓烷A2合成酶抑制活性是必需的。
• Novel Antiasthmatic Agents with Dual Activities of Thromboxane A2 Synthetase Inhibition and Bronchodilation. III. 4-(2-(5-Ethyl-2-thienyl))-2'-(2-(1-imidazolyl)ethyl)-1(2H)-phthalazinones.
  作者：Masahisa YAMAGUCHI、Takaki KOGA、Kenshi KAMEI、Michitaka AKIMA、Toshio KUROKI、Masatomo HAMANA、Nobuhiro OHI

  DOI：10.1248/cpb.42.1601

  日期：——

  Synthesis and pharmacological evaluation of novel 4-[2-(5-ethyl-2-thienyl)]-2-[2-(1-imidazolyl)ethyl]-1(2H)-phthalazinones are described. The phenyl moiety of the phthalazione skeleton was found to play an important role in both thromboxane A2 synthetase-inhibitory and bronchodilatory activities.

  描述了新型4-[2-(5-乙基-2-噻吩基)]-2-[2-(1-咪唑基)乙基]-1(2H)-二氮杂萘酮的合成和药理学评价。研究发现，二氮杂萘骨架的苯基部分在血栓素 A2 合成酶抑制和支气管扩张活性中发挥着重要作用。
• Substituted quinazolines and analogs and the use thereof
  申请人：Euro-Celtique, S.A.

  公开号：US20040162299A1

  公开（公告）日：2004-08-19

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus, Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  本发明涉及新型的喹唑啉和杂环化合物，它们是AMPA受体的拮抗剂或正向调节剂，用于治疗、预防或改善与中风、全身和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元损失，以及治疗或改善神经退行性疾病，包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病、帕金森病和唐氏综合症，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、惊厥、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及治疗或改善兴奋性氨基酸缺乏的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，以及作为认知和学习增强剂。
• Substituted quinazolines and analogs and use thereof
  申请人：Euro-Celtique S.A.

  公开号：US06465472B1

  公开（公告）日：2002-10-15

  The invention relates to novel quinazolines and heterocycles which are antagonists or positive modulators of AMPA receptors, and the use thereof for treating, preventing or ameliorating neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, as well as treating or ameliorating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease and Down's syndrome, treating, preventing or ameliorating the adverse consequences of the overstimulation of the excitatory amino acids, treating, preventing or ameliorating anxiety, psychosis, convulsions, chronic pain, glaucoma, retinitis, urinary incontinence, muscular spasm and inducing anesthesia, as well as for treating or ameliorating the adverse consequences of excitatory amino acid deficiency such as schizophrenia, myoclonus. Alzheimer's disease and malnutrition and neural maldevelopment, and as cognition and learning enhancers.

  本发明涉及新型的喹唑啉和杂环化合物，它们是AMPA受体的拮抗剂或正向调节剂，用于治疗、预防或改善与中风、全球和局部缺血、中枢神经系统创伤、低血糖和手术相关的神经元丢失，以及治疗或改善神经退行性疾病，包括阿尔茨海默病、肌萎缩性侧索硬化症、亨廷顿病、帕金森病和唐氏综合症，治疗、预防或改善兴奋性氨基酸过度刺激的不良后果，治疗、预防或改善焦虑、精神病、惊厥、慢性疼痛、青光眼、视网膜炎、尿失禁、肌肉痉挛和诱导麻醉，以及用于治疗或改善兴奋性氨基酸缺乏的不良后果，如精神分裂症、肌阵挛、阿尔茨海默病和营养不良和神经发育不良，以及作为认知和学习增强剂。